Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 5 Examples of biomarker-guided trials

Published byAlfredo Severino Masini Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 5 Examples of biomarker-guided trials"— Presentation transcript:

1 Figure 5 Examples of biomarker-guided trials
Figure 5 | Examples of biomarker-guided trials. When results of biomarker analysis are available before randomization, the next step is to consider whether a response to treatment is anticipated. If some efficacy is expected even in patients with negative biomarker results, all patients (stratified on the basis of biomarker results) are included for randomization (Trials 1 and 2). Otherwise, only participants with positive biomarkers are included in the randomization scheme (Trial 3). When biomarker results are not available before randomization (Trial 4), participants are first allocated to the treatment arms, and the biomarker assay is performed during the trial. In this case, the findings of the trial are analysed and stratified on the basis of the retrospective determination of biomarker positivity or negativity. Antman, E. M. & Loscalzo, J. (2016) Precision medicine in cardiology Nat. Rev. Cardiol. doi: /nrcardio

Download ppt "Figure 5 Examples of biomarker-guided trials"

Similar presentations

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 5 BMI and cardiorespiratory fitness levels

Figure 5 BMI and cardiorespiratory fitness levels
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 BMI and mortality in patients with heart failure

Figure 4 BMI and mortality in patients with heart failure
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 Two approaches to therapeutic genome editing

Figure 5 Two approaches to therapeutic genome editing
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 3 Global rates of sodium, fruit, and vegetable intake
Figure 4 Precision prescribing

Figure 4 Precision prescribing
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 2 Three-year survival rates on the basis of body composition

Figure 2 Three-year survival rates on the basis of body composition
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Similar presentations

Ads by Google